Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
ATC suffix |
|
ATC prefix |
|
ChemSpiderID |
|
DrugBank |
|
elimination half-life |
|
KEGG |
|
legal status |
|
legal UK |
|
legal US |
|
routes of administration |
|
tradename |
|
has abstract |
|
DailyMedID |
|
legal EU |
|
licence EU |
|
pregnancy AU |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
DrugBank |
|
KEGG |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |